Stents have been used to treat coronary artery disease (the build-up of plaque in coronary arteries) for decades and they have evolved significantly. The stenting process begins with balloon angioplasty during which a balloon catheter is navigated to the target site and inflated to widen the vessel and flatten the plaque, as illustrated in Figure 1a-1c. A second balloon catheter with a stent over the balloon is then navigated to the target site and deployed via balloon expansion, Figure 1d-1e). Finally the balloon is deflated and removed, leaving the stent in place to support the vessel, Figure 1f-1g. Early stents were made of medical grade stainless steel [1] and are known as bare metal stents (BMSs). Unfortunately the occurrence of restenosis (re-narrowing of the vessel via either an inflammatory reaction [2] or formation of a clot/thrombus [3]) was common after BMS implantation. For this reason attempts were made at coating stents with various compounds, e.g. gold, silicon carbide, titaniumnitride-oxide, etc. to make them more inert [3,4]. These stents are known as coated metal stents (CMSs); their efficacy results were mixed -in some cases yielding higher restenosis rates than BMSs [5]. The next step in stent evolution was the development of drug-eluting stents (DESs) which gradually release pharmaceutical agents after implantation to mitigate restenosis. However, clinical studies revealed that late stent thrombosis rates were higher in the case of DESs when compared with